- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01118299
AMPLATZER Cardiac Plug Clinical Trial
Amplatzer Cardiac Plug Clinical Trial
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90017
- Good Samaritan Hospital
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Denver
-
Littleton, Colorado, Verenigde Staten, 80120
- South Denver Cardiology Associates
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory Midtown Hospital and Emory University Hospital
-
Atlanta, Georgia, Verenigde Staten
- St. Joseph's Hospital and Research Institute
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa Hospitals & Clinics
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40506
- University of Kentucky
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Spectrum Health
-
Southfield, Michigan, Verenigde Staten, 48075
- Providence Hospital
-
-
Minnesota
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- St. Cloud Hospital/CentraCare Heart and Vascular Clinic
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- HealthEast St. Joseph's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- University of Pennsylvania
-
York, Pennsylvania, Verenigde Staten, 17405
- York Hospital
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29401
- Roper Hospital/PMG Research of Charleston
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Memorial Hermann Hospital
-
-
Wisconsin
-
Wausau, Wisconsin, Verenigde Staten, 54401
- Aspirus Heart & Vascular Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation
- Subject must be ≥18 years of age
- Subject must be on warfarin or dabigatran therapy
- Subject must be eligible for long term warfarin or dabigatran therapy
- Subject must have a CHADS(2) score of 2 or greater
Summary of Exclusion Criteria:
- Subject who requires warfarin or dabigatran for a condition other than AF
- Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel or ticagrelor
- Subject who has an absolute or relative contraindication to aspirin, or warfarin and dabigatran
- Subject with a New York Heart Association (NYHA) classification equal to IV
- Subject with an implanted or surgical repair atrial septal defect (ASD) device or patent foramen ovale (PFO) device
- Subject with aortic or mitral valve regurgitation of grade 2+ or greater
- Subject with left ventricular ejection fraction (LVEF) ≤30
- Subject with mitral or aortic prosthetic valve
- Subject with a history of hemorrhagic or aneurysmal stroke
- Subject with a history of previous radio frequency (RF) ablation for atrial fibrillation
- Subject with a body mass index (BMI) ≥40
- Subject with a history of acute or recent MI, or unstable angina, or coronary artery bypass graft surgery (within 6 months)
- Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Device
AMPLATZER Cardiac Plug
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
Actieve vergelijker: Optimal Medical Therapy (control)
Warfarin Dabigatran
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only
Tijdsspanne: From Randomization to Discharge Visit
|
An analysis comparing the rate of procedure related serious adverse events that occur in the device arm to a performance goal determined from literature reported rates for similar procedural techniques. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm below. The secondary endpoint analysis requirement was removed from the protocol. |
From Randomization to Discharge Visit
|
Long-term Safety - Device Arm Only
Tijdsspanne: Randomization to 2 year follow-up
|
All-Cause Mortality and Major Bleeds Through 2 years in device arm subjects only. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization to 2 year follow-up
|
Effectiveness Endpoint - Device Arm Only
Tijdsspanne: Randomization through 2 year follow up
|
Occurrence of ischemic stroke and peripheral thromboembolism in the device arm. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization through 2 year follow up
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CL00921
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Ischemische beroerte
-
Stanford UniversityVoltooidISCHEMIC CARDIOMYOPATHIEVerenigde Staten
-
Stanford UniversityGeneral ElectricVoltooidISCHEMIC CARDIOMYOPATHIEVerenigde Staten
Klinische onderzoeken op AMPLATZER Cardiac Plug
-
University Hospital Inselspital, BerneVoltooidIschemie | Coronaire hartziekte | Interne borst-coronaire anastomose | Circulatie, onderpandZwitserland
-
Johns Hopkins UniversityWervingPulmonale arterioveneuze malformatieVerenigde Staten
-
University Hospital Inselspital, BerneVoltooidIschemie | Coronaire hartziekte | Interne borst-coronaire anastomose | Circulatie, onderpandZwitserland
-
Abbott Medical DevicesVoltooidHartinfarct | Boezemfibrilleren | Trombo-embolieCanada, Italië, Spanje, Argentinië, België, Chili, Duitsland
-
University Hospital Inselspital, BerneVoltooidIschemie | Coronaire hartziekte | Interne borst-coronaire anastomose | Circulatie, onderpandZwitserland
-
Abbott Medical DevicesJapanese society of Congenital Interventional CardiologyWerving
-
Abbott Medical DevicesAanmelden op uitnodigingParavalvulaire aortaregurgitatieVerenigde Staten, Spanje, Nederland, Canada, Italië, Polen, Verenigd Koninkrijk
-
Abbott Medical DevicesActief, niet wervendPFO - Patent Foramen OvaleJapan
-
Abbott Medical DevicesIngetrokkenHartinfarct | Boezemfibrilleren | Linker boezemaanhangsel
-
Abbott Medical DevicesWervingPFO - Patent Foramen Ovale | VSD - Spierventriculair septumdefect | PIVSD - Spierventriculair septumdefect na infarct | ASS - AtriumseptumdefectSpanje, Duitsland, Polen, Frankrijk, Italië, Nederland, Zwitserland